Alexandria Sutera
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,159 and has fallen 98.5% since, to $17 in 2025.
Across 103 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$356
- Lilly USA, LLC$353
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$175
- Axonics, Inc.$168
- Amarin Pharma, Inc.$140
- Boehringer Ingelheim$131
- plus $678 from 20 others
What the payments were for
- Food & beverage$2,000100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $356 |
| Lilly USA, LLC | 17 | $353 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $175 |
| Axonics, Inc. | 2 | $168 |
| Amarin Pharma, Inc. | 7 | $140 |
| Boehringer Ingelheim | 8 | $131 |
| AbbVie | 5 | $97 |
| Bayer | 5 | $82 |
| Johnson & Johnson | 2 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $37 |
| Merck | 2 | $36 |
| GSK | 2 | $35 |
| Pfizer | 2 | $31 |
| AstraZeneca | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Novartis | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,000 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 31 | $166 |
| Ofloxacin | 11 | $156 |
| Azithromycin | 19 | $120 |
| Methylprednisolone | 18 | $100 |
| Tizanidine Hcl | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other medical in Tampa
- Sandra SnyderTampa$156K
- Christopher RayTampa$41K
- Kathryn KlossTampa$33K
- Susan FerreyTampa$16K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.